Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019045086) USE FOR SPECIFIC ANTIBODY FOR ACTIVE OR LATENT TGF-β1
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/045086 International Application No.: PCT/JP2018/032514
Publication Date: 07.03.2019 International Filing Date: 28.08.2018
IPC:
G01N 33/574 (2006.01) ,G01N 33/53 (2006.01) ,G01N 33/543 (2006.01) ,G01N 33/577 (2006.01) ,C07K 16/22 (2006.01) ,C12P 21/08 (2006.01)
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53
Immunoassay; Biospecific binding assay; Materials therefor
574
for cancer
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53
Immunoassay; Biospecific binding assay; Materials therefor
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53
Immunoassay; Biospecific binding assay; Materials therefor
543
with an insoluble carrier for immobilising immunochemicals
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53
Immunoassay; Biospecific binding assay; Materials therefor
577
involving monoclonal antibodies
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
22
against growth factors
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
P
FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
21
Preparation of peptides or proteins
08
Monoclonal antibodies
Applicants:
林化成株式会社 HAYASHI KASEI CO., LTD. [JP/JP]; 大阪府大阪市北区堂島浜1丁目2番1号 新ダイビル24階 24F Shin-daibiru Building, 1-2-1, Dojimahama, Kita-ku, Osaka-shi, Osaka 5300004, JP
Inventors:
水谷 隆之 MIZUTANI, Takayuki; JP
Agent:
高島 一 TAKASHIMA, Hajime; 大阪府大阪市中央区伏見町四丁目1番1号 明治安田生命大阪御堂筋ビル Meiji Yasuda Seimei Osaka Midosuji Bldg., 1-1, Fushimimachi 4-chome, Chuo-ku, Osaka-shi, Osaka 5410044, JP
Priority Data:
2017-16488929.08.2017JP
Title (EN) USE FOR SPECIFIC ANTIBODY FOR ACTIVE OR LATENT TGF-β1
(FR) UTILISATION D'UN ANTICORPS SPÉCIFIQUE POUR TGF-β1 ACTIF OU LATENT
(JA) 活性型もしくは潜在型TGF−β1特異的抗体の用途
Abstract:
(EN) The present invention provides an examination method for diagnosing cancer or fibrosis or diagnosing cancer malignancy or fibrosis progress, said examination method being characterized in that a sample from a person who has or may have cancer or fibrosis is made to come into contact with a first monoclonal antibody, which binds to active TGF-β1 but does not bind to latent TGF-β1 and includes (a1) a complementarity determining region (CDR) including the amino acid sequence represented by sequence number 1, (b1) a CDR including the amino acid sequence represented by sequence number 2, (c1) a CDR including the amino acid sequence represented by sequence number 3, (d1) a CDR including the amino acid sequence represented by sequence number 4, (e1) a CDR including the amino acid sequence represented by sequence number 5, and (f1) a CDR including the amino acid sequence represented by sequence number 6, and/or a second monoclonal antibody, which binds to latent TGF-β1 and LAP but does not bind to active TGF-β1 and includes (a2) a CDR including the amino acid sequence represented by sequence number 7, (b2) a CDR including the amino acid sequence represented by sequence number 8, (c2) a CDR including the amino acid sequence represented by sequence number 9, (d2) a CDR including the amino acid sequence represented by sequence number 10, (e2) a CDR including the amino acid sequence represented by sequence number 11, and (f2) a CDR including the amino acid sequence represented by sequence number 12, and the active TGF-β1 and/or latent TGF-β1 or LAP in the sample is specifically detected.
(FR) La présente invention concerne un procédé d'examen pour diagnostiquer un cancer ou une fibrose ou pour diagnostiquer une malignité cancéreuse ou une progression de fibrose, ledit procédé d'examen étant caractérisé en ce qu'un échantillon provenant d'une personne qui a ou peut avoir un cancer ou une fibrose est amené à entrer en contact avec un premier anticorps monoclonal, qui se lie au TGF-β1 actif mais ne se lie pas au TGF-β1 latent et comprend (a1) une région de détermination de complémentarité (CDR) contenant la séquence d'acides aminés représentée par le numéro de séquence 1, (b1) un CDR contenant la séquence d'acides aminés représentée par le numéro de séquence 2, (c1) un CDR contenant la séquence d'acides aminés représentée par le numéro de séquence 3, (d1) un CDR contenant la séquence d'acides aminés représentée par le numéro de séquence 4, (e1) un CDR contenant la séquence d'acides aminés représentée par le numéro de séquence 5, et (f1) un CDR contenant la séquence d'acides aminés représentée par le numéro de séquence 6, et/ou un deuxième anticorps monoclonal, qui se lie au TGF-β1 latent et au LAP mais ne se lie pas au TGF-β1 actif et comprend (a2) un CDR contenant la séquence d'acides aminés représentée par le numéro de séquence 7, (b2) un CDR contenant la séquence d'acides aminés représentée par le numéro de séquence 8, (c2) un CDR contenant la séquence d'acides aminés représentée par le numéro de séquence 9, (d2) un CDR contenant la séquence d'acides aminés représentée par le numéro de séquence 10, (e2) un CDR contenant la séquence d'acides aminés représentée par le numéro de séquence 11, et (f2) un CDR contenant la séquence d'acides aminés représentée par le numéro de séquence 12, et le TGF-β1 actif et/ou le TGF-β1 latent ou le LAP latent dans l'échantillon est détecté spécifiquement.
(JA) 本発明は、がんもしくは線維症患者、又はその疑いのある者由来の検体と、 以下の(a1)〜(f1)の相補性決定領域(CDR):(a1)配列番号1で表されるアミノ酸配列を含むCDR、(b1)配列番号2で表されるアミノ酸配列を含むCDR、(c1)配列番号3で表されるアミノ酸配列を含むCDR、(d1)配列番号4で表されるアミノ酸配列を含むCDR、(e1)配列番号5で表されるアミノ酸配列を含むCDR、及び(f1)配列番号6で表されるアミノ酸配列を含むCDRを含み、活性型TGF−β1に結合するが、潜在型TGF−β1には結合しない第1のモノクローナル抗体、及び/又は 以下の(a2)〜(f2)のCDR:(a2)配列番号7で表されるアミノ酸配列を含むCDR、(b2)配列番号8で表されるアミノ酸配列を含むCDR、(c2)配列番号9で表されるアミノ酸配列を含むCDR、(d2)配列番号10で表されるアミノ酸配列を含むCDR、(e2)配列番号11で表されるアミノ酸配列を含むCDR、及び(f2)配列番号12で表されるアミノ酸配列を含むCDRを含み、潜在型TGF−β1及びLAPに結合するが、活性型TGF−β1には結合しない第2のモノクローナル抗体とを接触させ、該検体中の活性型TGF−β1及び/又は潜在型TGF−β1もしくはLAPを特異的に検出することを特徴とする、がんもしくは線維症の診断、又はがんの悪性度もしくは線維化の進行度の診断のための検査方法を提供する。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)